Aveo Pharmaceuticals Liabilities 2024

Aveo Pharmaceuticals Aktienanalyse

What does Aveo Pharmaceuticals do?

Aveo Pharmaceuticals Inc. is a bio-pharmaceutical company focused on the development of new therapies for cancer patients. The company was founded in 2001 in Cambridge, Massachusetts and is listed on the NASDAQ stock exchange under the ticker symbol AVEO. The history of Aveo Pharmaceuticals began with the discovery of a growth factor responsible for the formation of blood vessels in tumors. In collaboration with Harvard Medical School and the Dana-Farber Cancer Institute, the company developed a new drug called Tivozanib, which can block this growth factor. Tivozanib has been tested as a potential treatment for various types of cancer, including kidney cancer, breast cancer, and lung cancer, and is currently in various stages of development. Aveo Pharmaceuticals employs a collaborative business model to involve scientists and researchers in the development of new therapies. The company works together with leading academic institutions and bio-pharmaceutical companies to accelerate and improve the drug development process. Aveo Pharmaceuticals is divided into different divisions that focus on the development of therapies for different types of cancer. These divisions include oncology, which focuses on the development of therapies for solid tumors, as well as hematology, which focuses on the development of therapies for blood cancer. Aveo Pharmaceuticals also has a pipeline of products in various stages of development. These products include both novel drugs and therapies that are already on the market. One of Aveo Pharmaceuticals' most promising products is the drug Tivozanib. Tivozanib is a kinase inhibitor specifically designed for the treatment of kidney cancer. The drug has proven to be effective in clinical trials and could soon be approved by the U.S. Food and Drug Administration (FDA). Tivozanib could improve both the quality of life and the survival rate of kidney cancer patients. Another promising drug from Aveo Pharmaceuticals is Ficlatuzumab, a drug specifically designed for the treatment of solid tumors. Ficlatuzumab targets the hepatocyte growth factor receptor (HGFR), which is overexpressed in various types of cancer such as breast cancer, lung cancer, and pancreatic cancer. The drug is currently in clinical trials and has the potential to become a new treatment option for cancer patients. Over the years, Aveo Pharmaceuticals has received numerous awards and recognitions, including being recognized as one of the "50 Most Innovative Companies in the World" by Technology Review and being included in the "Forbes 200 Best Small Companies in America" ranking. In summary, Aveo Pharmaceuticals is an innovative bio-pharmaceutical company focused on the development of vital therapies for cancer patients. Aveo Pharmaceuticals' collaborative business model has enabled the company to work closely with leading academic institutions and bio-pharmaceutical companies to develop new drugs that could improve the lives of cancer patients. With Tivozanib and Ficlatuzumab, Aveo Pharmaceuticals has two promising drugs in the pipeline that have the potential to change the face of cancer treatment. Aveo Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Aveo Pharmaceuticals's Liabilities

Aveo Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Aveo Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Aveo Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Aveo Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Aveo Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Aveo Pharmaceuticals stock

What is the level of liabilities of Aveo Pharmaceuticals this year?

Aveo Pharmaceuticals has a debt balance of 59.47 M USD this year.

What were the liabilities of Aveo Pharmaceuticals compared to the previous year?

The liabilities of Aveo Pharmaceuticals have increased by 0% dropped compared to the previous year.

What are the consequences of high debt for investors of Aveo Pharmaceuticals?

High liabilities can pose a risk for investors of Aveo Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Aveo Pharmaceuticals?

Low liabilities mean that Aveo Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Aveo Pharmaceuticals affect the company?

An increase in liabilities of Aveo Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Aveo Pharmaceuticals affect the company?

A decrease in the liabilities of Aveo Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Aveo Pharmaceuticals?

Some factors that can influence the liabilities of Aveo Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Aveo Pharmaceuticals so important for investors?

The liabilities of Aveo Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Aveo Pharmaceuticals take to modify the liabilities?

To change its liabilities, Aveo Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Aveo Pharmaceuticals pay?

Over the past 12 months, Aveo Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aveo Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aveo Pharmaceuticals?

The current dividend yield of Aveo Pharmaceuticals is .

When does Aveo Pharmaceuticals pay dividends?

Aveo Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aveo Pharmaceuticals?

Aveo Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aveo Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aveo Pharmaceuticals located?

Aveo Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aveo Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aveo Pharmaceuticals from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Aveo Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Aveo Pharmaceuticals in the year 2023?

In the year 2023, Aveo Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aveo Pharmaceuticals pay out the dividend?

The dividends of Aveo Pharmaceuticals are distributed in USD.